Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 11/20 | 0.64 |
| ▸ | PRKCA | P17252 | 10/20 | 0.64 |
| ▸ | PRKCH | P24723 | 8/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 8/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 8/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 8/20 | 0.64 |
| ▸ | PRKACA | P17612 | 4/20 | 0.53 |
| ▸ | PRKACG | P22612 | 4/20 | 0.53 |
| ▸ | PRKACB | P22694 | 4/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 4/20 | 0.53 |
| ▸ | CCND1 | P24385 | 4/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.53 |
| ▸ | PRKCG | P05129 | 2/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14823686 | 0.86 | PRKCB (0.53) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3254216 | 0.81 | CDK2 (0.72) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3139173 | 0.81 | CDK2 (0.60) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3546574 | 0.78 | PRKCB (0.79) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3541633 | 0.78 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3590073 | 0.78 | PRKCB (0.64) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3594020 | 0.75 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL13500448 | 0.73 | PRKCB (0.56) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| Ro-316233 SCHEMBL29373011 | 0.73 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| Ro-316233 SCHEMBL624896 | 0.73 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| EP-2094689-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | PRKCB 2976/4885PRKCA 3364/4885PRKCH 3124/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | PRKCB 3873/4885PRKCA 4215/4885PRKCH 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.